Obsidian Therapeutics
  • About Us
    • Overview
    • Our Vision
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Our Science
    • Overview
    • Our Pipeline
    • cytoDRiVE® PLATFORM
    • Publications
    • Partners
  • Our Lead Clinical Program
    • Overview
    • For Patients
    • Expanded Access Policy
    • OBX-115
  • News
  • Join Our Team
    • Overview
    • Our Culture
    • Testimonials
    • Benefits
    • Job Postings
  • Contact

News

Back to News
Previous
Next
March 5, 2024

Obsidian Therapeutics Announces Clinical & Preclinical Presentations at the American Association of Cancer Research Annual Meeting

CAMBRIDGE, Mass., March 5, 2024 – Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced presentations reporting initial clinical data from the ongoing first-in-human study of OBX-115 and preclinical data from our cytoDRiVE® platform demonstrating regulatable cytoTIL15 signal transduction in cis and trans, as well as the ability of a single drug-responsive domain (DRD) to coregulate two cytokines, LIGHT and mbIL15, in tumor-infiltrating lymphocytes (TIL) during the American Association of Cancer Research (AACR) Annual Meeting, which will be held April 5-10, 2024 in San Diego, CA.

These data follow the announcement of positive top-line results from the ongoing first-in-human, Phase 1 clinical trial evaluating the safety and efficacy of OBX-115, Obsidian’s lead engineered TIL cell therapy candidate, in patients with metastatic melanoma that has relapsed and/or is refractory to prior immune checkpoint inhibitor (ICI) therapy (NCT05470283).

 

The details of these posters are as follows:

Title: OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy induced deepening and durable responses without interleukin 2 (IL2) in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma

Presenting Author: Rodabe N Amaria, The University of Texas MD Anderson Cancer Center, Houston, TX

Poster: CT176, Tuesday April 9, 9:00 AM-12:30 PM PDT

 

Title: Trial in progress: A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma

Presenting Author: Sajeve S Thomas, Orlando Health Cancer Institute, Orlando, FL

Poster: CT285, Tuesday April 9, 1:30 PM-5:00 PM PDT

 

Title: Tumor-infiltrating lymphocytes (TIL) engineered with membrane-bound IL15 (cytoTIL15 cells) exhibit pharmacologically regulatable signal transduction in cis and trans

Presenting Author: Rachel Burga, Obsidian Therapeutics, Inc., Cambridge, MA

Poster: LB072, Sunday April 7, 1:30-5:00 PM PDT

 

Title: Tumor-infiltrating lymphocytes (TIL) engineered with regulatable membrane-bound IL15 (mbIL15) and LIGHT (TNFSF14) show enhanced efficacy in fibroblast-containing cold tumors

Presenting Author: Balazs Koscso, Obsidian Therapeutics, Inc., Cambridge, MA

Poster: LB065, Sunday April 7, 1:30-5:00 PM PDT

 

About OBX-115

Obsidian’s lead investigational cytoTIL15™ program, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15). OBX-115 has the potential to become a meaningful therapeutic option for patients with advanced or metastatic melanoma and other solid tumors by leveraging the expected benefits of mbIL15 and Obsidian’s proprietary, differentiated manufacturing process to enhance persistence, anti-tumor activity, and clinical safety of TIL cell therapy. OBX-115 is being investigated in two ongoing and enrolling clinical trials in advanced or metastatic melanoma and NSCLC (NCT05470283 and NCT06060613).

 

About Obsidian Therapeutics

Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian is headquartered in Cambridge, MA. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com and follow us on LinkedIn.

 

Obsidian Therapeutics Media Contact

Caroline Code

media@obsidiantx.com

+1 (857) 341-0901

Back to News
Obsidian Therapeutics
  • About Us
  • Our Science
  • Our Lead Clinical Program
  • News
  • Join Our Team
  • Contact

Privacy // Terms of Use
© 2025 Obsidian Therapeutics, Inc. All Rights Reserved.

Our programs, including OBX-115, and cytoDRIVE® Platform are investigational and have not been approved by the FDA or any other regulatory agency.

Our Pipeline Job Postings
We use cookies on our website to optimize your experience, analyze site usage, and to assist with our marketing activities. By continuing to navigate our website, you consent to the use of cookies, our privacy policy and terms of use.
Accept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT